Nuvation Bio down 9% after FDA approves Ibtrozi

Shares of Nuvation Bio (NUVB) are down 22c, or 9%, to 2.31 after the FDA approved Ibtrozi for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. JonesResearch stated after the approval was announced that warnings and precautions on the label are as expected for Ibtrozi, inline with the class of drugs, and better than peer drugs, such as Augtyro, Xalkori and Rozlytrek.